Works cited by this work
292 works
Work: Nanoparticle-Based PCSK9 Inhibition in Viral Infections: Evaluating Clinical Limitations and Advancing Therapeutic Strategies
Polymeric Nanoparticles for Drug Delivery
Maximilian A. Beach, Umeka Nayanathara, Yanting Gao +4
Review article20247 citationsABIThe Evolving Future of PCSK9 Inhibitors
Robert S. Rosenson, Robert A. Hegele, Sergio Fazio +1
Review article20184 citationsABIHIV Infection and the Risk of Acute Myocardial Infarction
Matthew S. Freiberg, Chung-Chou H. Chang, Lewis H. Kuller +25
Article20133 citationsABICurrent hurdles to the translation of nanomedicines from bench to the clinic
Snežana Đorđević, María Medel Gonzalez, Inmaculada Conejos‐Sánchez +6
Review article20213 citationsABIRecent advances in metal nanoparticles to treat periodontitis
Kamyar Nasiri, Seyed Mohammad Reza Masoumi, Sara Amini +7
Review article20233 citationsABIThe potential use of mesenchymal stem cells-derived exosomes as microRNAs delivery systems in different diseases
Elham Oveili, Somayeh Vafaei, Haniyeh Bazavar +4
Review article20233 citationsABIMesenchymal Stem Cell-based Scaffolds in Regenerative Medicine of Dental Diseases
Mohammad Kiarashi, Hannaneh Bayat, Seyed Abbas Shahrtash +6
Review article20243 citationsABIAn overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19
Saman Yasamineh, Hesam Ghafouri Kalajahi, Pooneh Yasamineh +10
Review article20223 citationsABIEffect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya +17
Article20132 citationsABINew Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Reindert F. Oostveen, Amit V. Khera, Sekar Kathiresan +5
Review article20232 citationsABILipid-based nanoparticle formulations for small molecules and RNA drugs
Ludger M. Ickenstein, Patrick Garidel
Review article20192 citationsABIMolecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Rainer Schulz, Klaus‐Dieter Schlüter, Ulrich Laufs
Review article20152 citationsABIPCSK9 induces a pro-inflammatory response in macrophages
Chiara Ricci, Massimiliano Ruscica, Marina Camera +10
Article20182 citationsABIPCSK9 and inflammation: a review of experimental and clinical evidence
Amir Abbas Momtazi‐Borojeni, Sarvenaz Sabouri-Rad, Antonio M. Gotto +5
Review article20192 citationsABIProprotein Convertase Subtilisin/Kexin Type 9
Chiara Macchi, Nicola Ferri, Cesare R. Sirtori +3
Review article20212 citationsABIPCSK9-targeted therapies: present and future approaches
Mahmoud Al Rifai, Christie M. Ballantyne
Review article20212 citationsABIMay statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
Roberto Scicali, Antonino Di Pino, Salvatore Piro +2
Review article20202 citationsABIStatins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
Fotios Barkas, Haralampos Milionis, Georgia Anastasiou +1
Review article20202 citationsABI